CSE Bulletin: Consolidation - Lobe Sciences Ltd.

CSE Bulletin: Consolidation - Lobe Sciences Ltd.

lobe sciences ltd. (the "Issuer") has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every six (6) pre-consolidated common shares.

As a result, the outstanding common shares of the Issuer will be reduced to approximately 38,230,000 common shares.

Further to the Issuer's news release dated June 6, 2022, the record date has been changed to June 10, 2022.

Trading will remain halted June 9, 2022 and resume on a consolidated basis June 10, 2022.

The name and symbol will not change.

Please note that all open orders will be cancelled at the close of business on June 9, 2022. Dealers are reminded to re-enter their orders taking into account the share consolidation.

_________________________________

lobe sciences ltd. (l'« émetteur ») a annoncé un regroupement de ses actions ordinaires émises et en circulation sur la base d'une (1) action ordinaire post-regroupement pour six (6) actions ordinaires pré-regroupement.

Par conséquent, les actions ordinaires en circulation de l'Émetteur seront réduites à environ 38 230 000 actions ordinaires.

Suite au communiqué de presse de l'Emetteur du 6 juin 2022, la date d'enregistrement a été reportée au 10 juin 2022.

Les échanges resteront interrompus le 9 juin 2022 et reprendront sur une base consolidée le 10 juin 2022.
Le nom et le symbole ne changeront pas.

Veuillez noter que tous les ordres ouverts seront annulés à la fermeture des bureaux le 9 juin 2022. Il est rappelé aux concessionnaires de saisir à nouveau leurs ordres en tenant compte du regroupement d'actions.

Trading on a Consolidated Basis/Négociation sur une base consolidée:

Le 10 juin/June 2022

Record Date/Date d'enregistrement:

Le 10 juin/June 2022

Symbol/Symbole:

LOBE

NEW/NOUVEAU CUSIP:

53946V 20 6

NEW/NOUVEAU ISIN:

CA53946V 20 6 6

Old/Vieux CUSIP & ISIN:

53946V107/CA53946V1076

 

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com.

Pour toute question ou information complémentaire, veuillez contacter Listings au 416 367-7340 ou par courriel à: Listings@thecse.com.

News Provided by Newsfile via QuoteMedia

Steadright Critical Minerals

Steadright Critical Minerals Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Steadright Critical Minerals (CSE:SCM)

Steadright Critical Minerals

Advancing high-grade mineral assets in Morocco with near-term cash flow and growth potential

Advancing high-grade mineral assets in Morocco with near-term cash flow and growth potential Keep Reading...
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its second quarter of... Keep Reading...
Pill labeled "GLP-1" on a $100 bill background.

As GLP-1 Brands Go Prime Time, Regulators Flag Growing Illicit Market

At Super Bowl LX, companies behind blockbuster GLP-1 medications spent tens of millions of dollars to court a mass audience. But as brand-name makers and telehealth platforms race to normalize and expand access, regulators on both sides are warning of a parallel surge in counterfeit, compounded,... Keep Reading...
Solvonis Therapeutics

Expansion of SVN-015 into Depression Following Positive Preclinical Data

Demonstrates antidepressant-like activity benchmarked against fluoxetine (Prozac®), supporting potential in patients with inadequate SSRI response

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces the expansion of its investigational compound SVN-015 into the treatment of depression, supported by preclinical data... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs for Investors in 2026

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies and the pharma market as a whole. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the... Keep Reading...
InMed Announces Results of 2025 Annual General and Special Meeting

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders... Keep Reading...
InMed Provides Update on BayMedica Commercial Business

InMed Provides Update on BayMedica Commercial Business

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.Recently, H.R. 5371, the "Continuing... Keep Reading...
Steadright Critical Minerals

Steadright Critical Minerals Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Interactive Chart

Latest Press Releases

Related News